 SALT LAKE CITY, May 26, 2021 PRNewswire -- Lipocine Inc. NASDAQ: LPCN, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the United States District Court for the District of Delaware Court has granted Clarus Therapeutics, Inc.s Clarus motion for Summary Judgment, finding the asserted claims of Lipocines U.S. patents 9,034,858; 9,205,057; 9,480,690; and 9,757,390 invalid for failure to satisfy the written description requirement of 35 U.S.C. 112. Clarus still has remaining claims before the Court. 